




















SUPPLEMENTAL TABLE 2

Newly FDA-approved Anticancer Agents: August 1, 2021-July 31, 2022

Type of Treatment	Generic Name	Trade Name	Approved For	Clinical Trial(s)	Formulation
Surgery, Chemotherapy, Radiotherapy	gallium Ga 68 gozetotide	Locametz	Certain type of prostate cancer	NCT03511664	
	lutetium Lu 177 vipivotide tetraxetan	Pluvicto	Certain type of prostate cancer	NCT03511664	
	pafolacianine	Cytalux	Certain type of ovarian cancer	NCT03180307	
Molecularly Targeted Therapy	asciminib	Scemblix	Certain type of leukemia	NCT03106779; NCT02081378	
	belzutifan	Welireg	Several tumors associated with the von Hippel-Lindau syndrome	NCT03401788	
	crizotinib	Xalkori	Certain type of inflammatory myofibroblastic tumors*	NCT00939770; NCT01121588	
	dabrafenib & trametinib	Tafinlar & Mekinist	Solid tumors carrying certain type of genetic mutation*	NCT02034110; NCT02465060; NCT02124772	
	ivosidenib†	Tibsovo	Certain type of bile duct cancer*	NCT02989857	
	mobocertinib†	Exkivity	Certain type of lung cancer	NCT02716116	
	rituximab	Rituxan	Certain type of lymphoma*	NCT01516580	
	sirolimus protein-bound particles	Fyarro	Certain type of perivascular epithelioid cell tumors*	NCT02494570	
	tisotumab vedotin-tftv	Tivdak	Certain type of cervical cancer	NCT03438396	
Immunotherapy	zanubrutinib	Brukina	Certain type of lymphoma*	NCT03053440; NCT03846427; NCT02343120	
	brexucabtagene autoleucel	Tecartus	Certain type of leukemia*	NCT02614066	
	ciltacabtagene autoleucel	Carvykti	Multiple myeloma	NCT03548207	
	dostarlimab-gxly†	Jemperli	Solid tumors with a specific genetic feature*	NCT02715284	
	relatlimab-rmbw	Opdualag	Certain type of melanoma	NCT03470922	
	tebentafusp-tebn	Kimmtrak	Certain type of ocular melanoma	NCT03070392	
Immunotherapy	tisagenlecleucel	Kymriah	Certain type of lymphoma*	NCT03568461	

*New cancer type approved 2021-2022

†Requires a companion diagnostic